EGFR and lung adenocarcinoma: A total of 250 patients with advanced lung adenocarcinoma (stage IIIc, n = 2; stage IVa, n = 92; stage IVb, n = 156) after progression on first- or second-generation EGFR TKIs were enrolled in our study.